Cargando…

Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer

BACKGROUND: Despite recent advances in the treatment for advanced prostate cancer, outcomes remain poor. This lack of efficacy has prompted the development of alternative treatment strategies. In the present study we investigate the effects of the multikinase inhibitor sorafenib in a genetically eng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Yutaka, De Velasco, Marco A, Kura, Yurie, Nozawa, Masahiro, Hatanaka, Yuji, Oki, Takashi, Ozeki, Takayuki, Shimizu, Nobutaka, Minami, Takafumi, Yoshimura, Kazuhiro, Yoshikawa, Kazuhiro, Nishio, Kazuto, Uemura, Hirotsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438623/ https://www.ncbi.nlm.nih.gov/pubmed/25953027 http://dx.doi.org/10.1186/s12967-015-0509-x

Ejemplares similares

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
por: De Velasco, Marco A., et al.
Publicado: (2016)

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer
por: De Velasco, Marco A., et al.
Publicado: (2014)

Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms
por: Shimizu, Nobutaka, et al.
Publicado: (2013)

Survey on lower urinary tract symptoms and sleep disorders in patients treated at urology departments
por: Shimizu, Nobutaka, et al.
Publicado: (2013)

Acotiamide hydrochloride hydrate added to combination treatment with an α-blocker and a cholinergic drug improved the QOL of women with acute urinary retention: case series
por: Sugimoto, Koichi, et al.
Publicado: (2017)

Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway
por: De Velasco, Marco A., et al.
Publicado: (2012)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

Reactivation of latent tuberculosis infection induced by cabazitaxel in a patient with prostate cancer: A case report
por: Hashimoto, Mamoru, et al.
Publicado: (2019)

Sarcopenia and Visceral Obesity are Significantly Related to Severe Storage Symptoms in Geriatric Female Patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model
por: Sakai, Kazuko, et al.
Publicado: (2021)

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
por: Matsumura, Naoki, et al.
Publicado: (2021)

A case of neuroendocrine tumor at the external urethral meatus after total cystectomy
por: Miki, Koji, et al.
Publicado: (2023)

Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients
por: Hashimoto, Mamoru, et al.
Publicado: (2021)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Procalcitonin as a useful marker to decide upon intervention for urinary tract infection
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis
por: Sakai, Kazuko, et al.
Publicado: (2021)

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
por: Yoshimura, K, et al.
Publicado: (2013)

Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system
por: Harashima, Nanae, et al.
Publicado: (2014)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2013)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome
por: Fujita, Kazutoshi, et al.
Publicado: (2023)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2022)

Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment
por: Kaibori, Masaki, et al.
Publicado: (2016)

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
por: Kim, Do Hyung, et al.
Publicado: (2013)

Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats
por: Ting, Chin-Tsung, et al.
Publicado: (2021)

Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
por: Minami, Kazuhiro, et al.
Publicado: (2019)

Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study
por: Takahashi, Hiroaki, et al.
Publicado: (2018)

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine
por: Hatanaka, Yutaka, et al.
Publicado: (2021)

Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma
por: Kato, Tatsuya, et al.
Publicado: (2018)

Effective prevention of sorafenib-induced hand–foot syndrome by dried-bonito broth
por: Kamimura, Kenya, et al.
Publicado: (2018)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lvu05vs16f74kpv9qhk5s34jbh